Biocon Returns to Profitability as Revenue Growth Accelerates
Biocon posted a strong 16.3% YoY revenue increase and a return to profit, marking a significant turnaround from last year's loss.
Biocon's Q1 FY27 results show robust revenue growth and a sharp swing to profitability, with net profit margin recovering to 8.4% from a negative base a year ago.
Biocon has started FY27 on a solid note, with revenue growth accelerating and a decisive return to profitability. The biopharma leader's latest quarter marks a sharp turnaround from the loss reported in the same period last year, driven by consistent top-line expansion.
The company's revenue for Q1 FY27 reached ₹624.5 crore, a 16.3% increase year-on-year and a 3.3% sequential improvement. More importantly, profit swung to ₹52.2 crore from a loss of ₹8.3 crore in Q1 FY26. This recovery pushed the net profit margin to a healthy 8.4%, a significant 990 basis point improvement from the negative margin a year ago.
A look at the recent quarterly performance shows the path to this recovery:
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ1 FY27 | PreviousQ4 FY26 | Same quarter LYQ1 FY26 |
|---|---|---|---|
| Period Ended | June 2026 | March 2026 | June 2025 |
| Revenue (₹ Cr) | 624.5YoY +16% | 604.7 | 537.1 |
| Profit (₹ Cr) | 52.2YoY +729% | 51.0 | -8.3 |
| Net Profit Margin (%) | 8.4YoY +660% | 8.4 | -1.5 |
The table highlights the volatility in profitability over the past year, with two quarters of strong profit followed by a deep loss in Q3 FY26. The last two quarters have stabilized, showing consistent revenue and profit. On a trailing twelve-month (TTM) basis, revenue stands at ₹2,433.8 crore with a profit of ₹97.7 crore, resulting in a TTM net profit margin of 4.0%.
This earnings recovery has been accompanied by strong stock performance, with shares up 21.1% over the past year. The key question now is whether Biocon can sustain this positive momentum and translate it into more consistent bottom-line growth in the quarters ahead.
Live Chart
· BIOCON
(BSE)
ISIN: INE376G01013
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.